Related Experiment Video
Updated: May 13, 2026
10:37
Development of Recombinant Proteins to Treat Chronic Pain
Published on: April 11, 2018
9.5K
Inflammatory pain resolution by mouse serum-derived small extracellular vesicles.
Zhucheng Lin1, Xuan Luo1, Jason R Wickman1
1Department of Pharmacology & Physiology, Drexel University College of Medicine, 245 North 15th Street, Mail Stop 488, Room 8223, Philadelphia, PA 19102, USA.
Brain, Behavior, and Immunity
|September 30, 2024
Summary
Small extracellular vesicles (sEVs) show promise for pain management by delivering therapeutic cargo. Studies show sEVs can modulate pain through opioid signaling and immune cell changes, offering new therapeutic avenues.
Area of Science:
- Biomedical research
- Pain management
- Extracellular vesicle biology
Background:
- Current chronic pain treatments have limited efficacy and significant side effects.
- Small extracellular vesicles (sEVs), also known as exosomes, are being explored for their potential to deliver therapeutic biomolecules for pain resolution.
- The source and cargo of sEVs influence their effects, necessitating comprehensive characterization.
Purpose of the Study:
- To comprehensively analyze sEV characterization, miRNA, and protein markers from different sources.
- To investigate the short- and long-term effects of mouse serum-derived sEVs on pain modulation.
- To explore the mechanisms underlying sEV-mediated pain attenuation.
Main Methods:
- Multi-modal analysis of sEVs (characterization, miRNAs, protein markers).
- Intrathecal injection of sEVs from naïve or spared nerve injury (SNI) model mice into recipient mice.
- Assessment of pain thresholds, opioid signaling blockade (naltrexone), and endogenous opioid peptide analysis (leu-enkephalin).
- Prophylactic sEV injection prior to inflammatory pain induction (Complete Freund's Adjuvant - CFA).
- Analysis of immune cell populations in spinal cord and dorsal root ganglion using ChipCytometry and flow cytometry.
Main Results:
- Intrathecal sEV injection transiently increased mechanical pain thresholds, mediated by opioid signaling and the presence of leu-enkephalin.
- sEVs from female mice contained higher leu-enkephalin levels than male mice.
- Prophylactic sEV administration accelerated recovery from CFA-induced inflammatory pain.
- sEV treatment led to alterations in immune cell populations, including an increase in CD206+ macrophages in the spinal cord.
Conclusions:
- Mouse serum-derived sEVs can modulate pain through opioid signaling pathways.
- sEVs possess both short-term analgesic effects and long-term pain resolution capabilities.
- sEVs influence immune cell responses in the central nervous system, contributing to pain attenuation.
- This study highlights the therapeutic potential of sEVs as a novel strategy for chronic pain management.
